Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells

Bai, Yaling; Zhang, Junxia; Xu, Jinyi; Cui, Liwen; Zhang, Huiran; Zhang, Shenglei; Feng, Xiaowei

doi:10.3892/br.2015.473

Cited by 33 publications

(33 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CAC has been shown to be associated with left ventricular diastolic dysfunction a major cause of HF with preserved ejection fraction in the elderly [ 29 ]; prospective studies have shown CAC to be associated with increased risk of incident HF [ 30 , 31 ]. Animal and experimental models have shown that magnesium prevents vascular calcification in aortic vascular smooth muscle cells [ 32 , 33 ]. Serum magnesium has been shown to be inversely related to CAC in the general population [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study

et al. 2018

View full text Add to dashboard Cite

To examine the association between serum magnesium and incident heart failure (HF) in older men and investigate potential pathways including cardiac function, inflammation and lung function. Prospective study of 3523 men aged 60–79 years with no prevalent HF or myocardial infarction followed up for a mean period of 15 years, during which 268 incident HF cases were ascertained. Serum magnesium was inversely associated with many CVD risk factors including prevalent atrial fibrillation, lung function (FEV1) and markers of inflammation (IL-6), endothelial dysfunction (vWF) and cardiac dysfunction [NT-proBNP and cardiac troponin T (cTnT)]. Serum magnesium was inversely related to risk of incident HF after adjustment for conventional CVD risk factors and incident MI. The adjusted hazard ratios (HRs) for HF in the 5 quintiles of magnesium groups were 1.00, 0.72 (0.50, 1.05), 0.85 (0.59, 1.26), 0.76 (0.52, 1.11) and 0.56 (0.36, 0.86) respectively [p (trend) = 0.04]. Further adjustment for atrial fibrillation, IL-6, vWF and FEV1 attenuated the association but risk remained significantly reduced in the top quintile (≥ 0.87 mmol/l) compared with the lowest quintile [HR 0.62 (0.40, 0.97)]. Adjustment for NT-proBNP and cTnT attenuated the association further [HR 0.70 (0.44, 1.10)]. The benefit of high serum magnesium on HF risk was most evident in men with ECG evidence of ischaemia [HR 0.29 (0.13, 0.68)]. The potential beneficial effect of high serum magnesium was partially explained by its favourable association with CVD risk factors. Further studies are needed to investigate whether serum magnesium supplementation in older adults may protect from the development of HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Magnesium plays an important role in vascular health, with normal magnesium homeostasis in VSMC maintained via TRPM7 cation channels. Magnesium prevents posttranscriptional changes in VSMC differentiation and apoptosis and up‐regulates VC inhibitors (MGP and osteopontin), whilst counteracting expression of osteogenic transcription factors (BMP‐2, RUNX2, Msh homeobox 2, and SRY‐ box 9), bone proteins and genes associated with matrix mineralization (osteocalcin and TNAP) . In animal models of VC, dietary supplementation with magnesium results in marked reduction in VC and mortality, improved mineral metabolism, including lowering of PTH, as well as improvement in renal function …”

Section: Future Potential Management For Vc In Clinical Evaluationmentioning

confidence: 99%

Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis

Ruderman

Holt

Hewitson

et al. 2018

Seminars in Dialysis

View full text Add to dashboard Cite

Patients with CKD have accelerated vascular stiffening contributing significantly to excess cardiovascular morbidity and mortality. Much of the arterial stiffening is thought to involve vascular calcification (VC), but the pathogenesis of this phenomenon is complex, resulting from a disruption of the balance between promoters and inhibitors of calcification in a uremic milieu, along with derangements in calcium and phosphate metabolic pathways. Management of traditional cardiovascular risk factors to reduce VC may be influential but has not been shown to significantly improve mortality. Control of mineral metabolism may potentially reduce the burden of VC, although using conventional approaches of restricting dietary phosphate, administering phosphate binders, and use of active vitamin D and calcimimetics, remains controversial because recommended biochemical targets are hard to achieve and clinical relevance hard to define. Increasing time on dialysis is perhaps another therapy with potential effectiveness in this area. Despite current treatments, cardiovascular morbidity and mortality remain high in this group. Novel therapies for addressing VC include magnesium and vitamin K supplementation, which are currently being investigated in large randomized control trials. Other therapeutic targets include crystallization inhibitors, ligand trap for activin receptors and BMP-7. This review summarizes current treatment strategies and therapeutic targets for the future management of VC in patients with CKD.

show abstract

“…During sexual stimulation, the relaxation in the smooth muscles of the arteries that supply blood to erectile tissues is important for erection (26). Studies on this subject have reported that Mg plays an important role in vascular tonus by the Ca-channel blockade in vascular smooth muscle cells (27,28). In addition, the relationship has been reported between reduced Mg levels and abnormal growth of vascular muscle cell, muscle contraction, inflammation, and fibrosis (29).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Serum Magnesium Levels in Patients with Erectile Dysfunction and Healthy Peers

Benli̇¹,

Çırakoğlu²,

Ayyıldız³

2018

JAREM

View full text Add to dashboard Cite

Objective: Erectile dysfunction (ED) is a very common health problem among men that disrupts the quality of life. The aim of this study was to investigate whether serum magnesium levels in patients with ED are different from those in healthy individuals. Methods:The study accessed the data of 344 patients who applied to the urology clinic from 2014 to 2016. Patients were divided into two groups: patients with ED, Group 1 (n=155) and those without ED, Group 2 (control; n=189). Characteristics such as patients' age, additional diseases, and smoking habits were recorded and compared between the two groups along with laboratory parameters such as levels of serum magnesium, calcium, and inflammatory markers. Sexual situation was assessed with the SHIM-5 form.Results: Patients aged 63.15±8.90 years were included in Group 1 and those aged 61.63±8.01 years were included in Group 2 (p=0.101). There were no differences between the groups in terms of BMI and waist circumference (p>0.05). Serum magnesium levels were 1.94±0.20 and 2.00±0.17 mg/dl in groups 1 and 2, respectively (p=0.008). WBC value for inflammatory makers were 6.94±1.74 and 6.58±1.43 in groups 1 and 2, respectively (p=0.04).Conclusion: Our study found that serum magnesium values were reduced in ED patients than in the control group. Therefore, it may be beneficial to determine serum magnesium values in ED patients. Additionally, serum magnesium values may be used as markers for the early identification of patients at risk.

show abstract

Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells

Cited by 33 publications

References 39 publications

Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study

Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study

Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis

Comparison of Serum Magnesium Levels in Patients with Erectile Dysfunction and Healthy Peers

Contact Info

Product

Resources

About